Stock Analiz

Biocryst Pharmaceuticals Inc. (BCRX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Biocryst Pharmaceuticals’s revenue went from $26M in fiscal 2016 to $875M in fiscal 2025, growth of about 47.6% a year.

Net income in fiscal 2025 was $264M, a net margin of 30.2%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $962M and net income -$360M.

Free cash flow was $345M in fiscal 2025 and positive in 1 of the 10 years shown.

The diluted share count rose 296486% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $26M162017: $25M172018: $21M182019: $49M192020: $18M202021: $157M212022: $271M222023: $331M232024: $451M242025: $875M25$875M
Net income
2016: -$55M162017: -$66M172018: -$101M182019: -$109M192020: -$183M202021: -$184M212022: -$247M222023: -$227M232024: -$89M242025: $264M25$264M
Free cash flow
2016: -$59M162017: -$41M172018: -$93M182019: -$90M192020: -$136M202021: -$145M212022: -$163M222023: -$97M232024: -$53M242025: $345M25$345M
EPS (diluted)
2016: $-750.00162017: $-780.00172018: $-980.00182019: $-940.00192020: $-1.09202021: $-1.03212022: $-1.33222023: $-1.18232024: $-0.43242025: $1.2125$1.21

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$962M$875M$451M$331M$271M$157M$18M$49M$21M$25M$26M
Gross profit$941M$856M$438M$327M$264M$150M$16M$45M—$24M$24M
Operating income-$289M$341M-$3M-$104M-$148M-$178M-$175M-$99M-$94M-$57M-$49M
Net income-$360M$264M-$89M-$227M-$247M-$184M-$183M-$109M-$101M-$66M-$55M
EPS (diluted)$-1.28$1.21$-0.43$-1.18$-1.33$-1.03$-1.09$-940.00$-980.00$-780.00$-750.00
R&D$211M$166M$175M$217M$253M$209M$123M$107M$85M$67M$61M
Revenue growth—+94.1%+36.0%+22.4%+72.3%+782.4%−63.5%+136.5%−18.0%−4.4%−45.4%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$367M$347M-$52M-$95M-$162M-$142M-$135M-$90M-$93M-$41M-$53M
Capital spending-$2M-$2M-$1M-$2M-$1M-$2M-$514000-$343000-$366000-$328000-$5M
Free cash flow$366M$345M-$53M-$97M-$163M-$145M-$136M-$90M-$93M-$41M-$59M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$69M$85M$65M$56M$45M$35M$15M$18M$9M$13M$8M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$275M$321M$389M$424M$508M$300M$136M$104M$114M$55M
Debt—$9M$324M$313M$237M$306M$155M$50M$30M$29M$28M
Equity—-$119M-$476M-$456M-$295M-$107M-$19M$38M$49M$84M$2M
Total assets—$514M$490M$517M$550M$588M$335M$175M$147M$178M$90M
Shares (diluted)268M219M207M192M186M179M167M116M0M0M0M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin97.9%97.8%97.3%98.7%97.6%95.4%91.3%92.4%—95.5%91.3%
Operating margin-30.1%39.0%-0.6%-31.3%-54.8%-113.1%-981.1%-203.7%-456.2%-228.0%-184.4%
Net margin-37.4%30.2%-19.7%-68.4%-91.2%-117.1%-1026.4%-223.0%-490.2%-261.2%-209.2%
FCF margin38.0%39.4%-11.8%-29.4%-60.3%-92.0%-761.4%-184.1%-450.0%-164.7%-222.8%
ROIC—————-70.6%-129.0%-112.7%-93.9%-40.3%-128.8%
ROE—-221.5%18.7%49.7%83.9%172.0%949.1%-284.7%-205.7%-78.5%-3494.6%

Frequently asked questions

What is Biocryst Pharmaceuticals’s annual revenue?

$875M in fiscal 2025 and $962M over the twelve months to September 30, 2026.

How much profit does Biocryst Pharmaceuticals make?

Net income was $264M in fiscal 2025 (net margin 30.2%).

Is Biocryst Pharmaceuticals’s revenue growing?

Yes: revenue rose 94.1% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.